Wy 26392

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 585428

CAS#: 82059-29-8

Description: Wy 26392 is an alpha 2 adrenoceptors antagonist that increase central sympathetic tone and blood pressure in low doses.


Chemical Structure

img
Wy 26392
CAS# 82059-29-8

Theoretical Analysis

MedKoo Cat#: 585428
Name: Wy 26392
CAS#: 82059-29-8
Chemical Formula: C17H27ClN2O2S
Exact Mass: 358.1482
Molecular Weight: 358.925
Elemental Analysis: C, 56.89; H, 7.58; Cl, 9.88; N, 7.80; O, 8.91; S, 8.93

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Wy 26392; Wy26392; Wy-26392

IUPAC/Chemical Name: N-[(11bR)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]-N-methylpropane-1-sulfonamide;hydrochloride

InChi Key: PAXYOGKTTMRRMP-PKESZJFOSA-N

InChi Code: InChI=1S/C17H26N2O2S.ClH/c1-3-12-22(20,21)18(2)15-9-11-19-10-8-14-6-4-5-7-16(14)17(19)13-15;/h4-7,15,17H,3,8-13H2,1-2H3;1H/t15?,17-;/m1./s1

SMILES Code: CCCS(=O)(N(C1CCN2CCC3=CC=CC=C3[C@@]2([H])C1)C)=O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 358.925 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Paciorek PM, Pierce V, Shepperson NB, Waterfall JF. An investigation into the selectivity of a novel series of benzoquinolizines for alpha 2-adrenoceptors in vivo. Br J Pharmacol. 1984 May;82(1):127-34. PubMed PMID: 6329385; PubMed Central PMCID: PMC1987241.

2: Ramage AG, Tomlinson A. The effect of yohimbine, WY 26392 and idazoxan on sympathetic nerve activity. Eur J Pharmacol. 1985 Feb 26;109(2):153-60. PubMed PMID: 2859996.

3: Ramage AG. The mechanism of the sympathoinhibitory action of urapidil: role of 5-HT1A receptors. Br J Pharmacol. 1991 Apr;102(4):998-1002. PubMed PMID: 1855130; PubMed Central PMCID: PMC1917978.

4: Jurcovicová J, Le T, Krulich L. The paradox of alpha 2 adrenergic regulation of prolactin (PRL) secretion. II. PRL-releasing action of the alpha 2 receptor antagonists. Brain Res Bull. 1989 Dec;23(6):425-32. PubMed PMID: 2575440.

5: Fozard JR, Mir AK, Middlemiss DN. Cardiovascular response to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in the rat: site of action and pharmacological analysis. J Cardiovasc Pharmacol. 1987 Mar;9(3):328-47. PubMed PMID: 2437400.

6: Bill DJ, Hughes IE, Stephens RJ. The thermogenic actions of alpha 2-adrenoceptor agonists in reserpinized mice are mediated via a central postsynaptic alpha 2-adrenoceptor mechanism. Br J Pharmacol. 1989 Jan;96(1):133-43. PubMed PMID: 2564288; PubMed Central PMCID: PMC1854293.

7: Hamilton CA, Reid JL, Yakubu MA. [3H]yohimbine and [3H]idazoxan bind to different sites on rabbit forebrain and kidney membranes. Eur J Pharmacol. 1988 Feb 9;146(2-3):345-8. PubMed PMID: 3371405.

8: Berthold H, Fozard JR, Engel G. 5-HT1 receptor agonists attenuate the naloxone-induced jumping behaviour in morphine-dependent mice. Eur J Pharmacol. 1989 Mar 14;162(1):19-27. PubMed PMID: 2566495.

9: Dickinson KE, McKernan RM, Miles CM, Leys KS, Sever PS. Heterogeneity of mammalian alpha 2-adrenoceptors delineated by [3H]yohimbine binding. Eur J Pharmacol. 1986 Jan 29;120(3):285-93. PubMed PMID: 3005004.

10: Gower AJ, Tricklebank MD. Alpha 2-adrenoceptor antagonist activity may account for the effects of buspirone in an anticonflict test in the rat. Eur J Pharmacol. 1988 Oct 11;155(1-2):129-37. PubMed PMID: 2907485.

11: Shepperson NB. Alpha 2-adrenoceptor agonists potentiate responses mediated by alpha 1-adrenoceptors in the cat nictitating membrane. Br J Pharmacol. 1984 Oct;83(2):463-9. PubMed PMID: 6148985; PubMed Central PMCID: PMC1987131.

12: McKernan RM, Dickinson KE, Miles CM, Sever PS. Heterogeneity between soluble human and rabbit splenic alpha 2-adrenoceptors. Biochem Pharmacol. 1986 Oct 15;35(20):3517-23. PubMed PMID: 2876709.

13: Oyekan AO, Botting JH. Adrenaline inhibits adenosine diphosphate induced intravascular aggregation of rat platelets through stimulation of alpha 2 adrenoceptors. Cardiovasc Res. 1991 May;25(5):431-7. PubMed PMID: 1677313.

14: McAdams RP, Waterfall JF. The effect of age on the sensitivity of pre- and postsynaptic alpha-adrenoceptors to agonists and antagonists in the rat. Naunyn Schmiedebergs Arch Pharmacol. 1986 Dec;334(4):430-5. Erratum in: Naunyn Schmiedebergs Arch Pharmacol 1987 Apr;335(4):480. PubMed PMID: 2881219.

15: Lattimer N, McAdams RP, Rhodes KF, Sharma S, Turner SJ, Waterfall JF. Alpha 2-adrenoceptor antagonism and other pharmacological antagonist properties of some substituted benzoquinolizines and yohimbine in vitro. Naunyn Schmiedebergs Arch Pharmacol. 1984 Oct;327(4):312-8. PubMed PMID: 6151116.

16: Paciorek PM, Shepperson NB. alpha 1-Adrenoceptor agonist activity of alpha 2-adrenoceptor antagonists in the pithed rat preparation. Br J Pharmacol. 1983 May;79(1):12-4. PubMed PMID: 6135473; PubMed Central PMCID: PMC2044847.

17: Botting JH, Oyekan AO, Hammady F. Inhibition of intravascular platelet aggregation in the rat by adrenaline. Pol J Pharmacol Pharm. 1990 May-Jun;42(3):291-9. PubMed PMID: 2263536.

18: Waterfall JF, Rhodes KF, Lattimer N. Studies of alpha 2-adrenoceptor antagonist potency in vitro: comparisons in tissues from rats, rabbits, dogs and humans. Clin Sci (Lond). 1985;68 Suppl 10:21s-24s. PubMed PMID: 2857614.

19: Paciorek PM, Shepperson NB. The alpha 2-adrenoceptor selectivities and haemodynamic effects of WY26392 and yohimbine in the anaesthetised dog. Eur J Pharmacol. 1985 Apr 2;110(2):191-201. PubMed PMID: 2859215.